Summary by Futu AI
Granahan Investment Management LLC, an investment adviser based in Massachusetts, has filed a Schedule 13G with the Securities and Exchange Commission on February 14, 2024, indicating a significant stake in bluebird bio, Inc. As of December 31, 2023, Granahan Investment Management reported beneficial ownership of 8,077,697 shares of bluebird bio's common stock, representing 7.38% of the company's class. The filing, made under Rule 13d-1(b), shows that Granahan has sole voting power over 6,741,868 shares and sole dispositive power over all 8,077,697 shares. The investment firm has declared that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of bluebird bio.